Announced
Financials
Sources
Tags
Pending
Majority
Single Bidder
China
pharmaceutical
Pharmaceuticals
Friendly
Acquisition
Cross Border
Private
Synopsis
AstraZeneca, a pharmaceutical company, agreed to acquire LaNova Medicines, a clinical-stage innovative drug research and development company. Financial terms were not disclosed. “LaNova Medicines has a strong focus on discovering and developing innovative medicines in the ADC and immuno-oncology fields. We’re excited to reach this agreement with AstraZeneca," Crystal Qin, LaNova Medicines Founder, Chair and CEO.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.